The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α-Synuclein Levels in Parkinson's Disease: A Meta-Analysis

被引:61
|
作者
Zhou, Bo [1 ]
Wen, Min [2 ]
Yu, Wen-Feng [3 ]
Zhang, Chun-Lin [1 ]
Jiao, Ling [4 ]
机构
[1] Guiyang Med Univ, Dept Biol, Guiyang 550004, Guizhou, Peoples R China
[2] Guiyang Med Univ, Dept Anat, Guiyang 550004, Guizhou, Peoples R China
[3] Guiyang Med Univ, Dept Mol Biol, Guiyang 550004, Guizhou, Peoples R China
[4] Guiyang Med Univ, Dept Neurol, Affiliated Hosp, Guiyang 550004, Guizhou, Peoples R China
关键词
ELEVATED LEVELS; BIOMARKERS; OLIGOMERS; NEUROTOXICITY; DEMENTIA; GENETICS;
D O I
10.1155/2015/567386
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Several recent studies showed that alpha-syn might be a potential diagnostic biomarker for PD in human cerebrospinal fluid (CSF), but the results were inconsistent. The purpose of this meta-analysis was to investigate the diagnostic and differential diagnosis efficacy of CSF alpha-syn in PD. Studies which measured CSF alpha-syn or alpha-syn oligomers in patients with PD and met the inclusion criteria were included in the analysis. Results of the meta-analysis indicated that mean concentration of CSF alpha-syn was significantly lower in PD compared to controls and significantly higher in PD compared to multiple system atrophy (MSA). No significant difference in mean concentration of CSF alpha-syn was found between PD and dementia with Lewy bodies (DLB). Mean concentration of CSF alpha-syn was slightly decreased in PD compared to progressive supranuclear palsy (PSP). Mean concentration of CSF alpha-syn oligomers was significantly higher in PD than control. These results support the findings that CSF alpha-syn may be a potential diagnostic and differential diagnosis biomarker in PD compared to control and MSA but not DLB. Furthermore, alpha-syn oligomer may represent a better biomarker for diagnosis of PD.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Meta-analysis of α synuclein/NACP polymorphism in Parkinson's disease in Japan
    Mizuta, I
    Nishimura, M
    Mizuta, E
    Yamasaki, S
    Ohta, M
    Kuno, S
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 73 (03): : 350 - +
  • [32] Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson's disease dementia
    Gmitterova, Karin
    Gawinecka, Joanna
    Llorens, Franc
    Varges, Daniela
    Valkovic, Peter
    Zerr, Inga
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2020, 270 (04) : 461 - 470
  • [33] Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson’s disease dementia
    Karin Gmitterová
    Joanna Gawinecka
    Franc Llorens
    Daniela Varges
    Peter Valkovič
    Inga Zerr
    European Archives of Psychiatry and Clinical Neuroscience, 2020, 270 : 461 - 470
  • [34] Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity
    van Dijk, K. D.
    Bidinosti, M.
    Weiss, A.
    Raijmakers, P.
    Berendse, H. W.
    van de Berg, W. D. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 (03) : 388 - 394
  • [35] Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis
    Eusebi, Paolo
    Hansson, Oskar
    Paciotti, Silvia
    Orso, Massimiliano
    Chiasserini, Davide
    Calabresi, Paolo
    Blennow, Kaj
    Parnetti, Lucilla
    BMJ OPEN, 2017, 7 (11):
  • [36] Genome-Wide Meta-Analysis of Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Parkinson's Disease Cohorts
    Ta, Michael
    Blauwendraat, Cornelis
    Antar, Tarek
    Leonard, Hampton L.
    Singleton, Andrew B.
    Nalls, Mike A.
    Iwaki, Hirotaka
    MOVEMENT DISORDERS, 2023, 38 (09) : 1697 - 1705
  • [37] Plasma alpha-synuclein levels in patients with Parkinson’s disease: a systematic review and meta-analysis
    Anastasia Bougea
    Leonidas Stefanis
    George P Paraskevas
    Evangelia Emmanouilidou
    Kostas Vekrelis
    Elisabeth Kapaki
    Neurological Sciences, 2019, 40 : 929 - 938
  • [38] Value of cerebrospinal fluid -synuclein species as biomarker in Parkinson's diagnosis and prognosis
    Parnetti, Lucilla
    Cicognola, Claudia
    Eusebi, Paolo
    Chiasserini, Davide
    BIOMARKERS IN MEDICINE, 2016, 10 (01) : 35 - 49
  • [39] Cerebrospinal fluid protein tan levels in the differential diagnosis of Alzheimer's disease
    Schönknecht, P
    Pantel, J
    Werle, E
    Hartmann, T
    Essig, M
    Baudendistel, K
    Beyreuther, K
    Schröder, J
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2000, 68 (10) : 439 - 446
  • [40] Plasma alpha-synuclein levels in patients with Parkinson's disease: a systematic review and meta-analysis
    Bougea, Anastasia
    Stefanis, Leonidas
    Paraskevas, George P.
    Emmanouilidou, Evangelia
    Vekrelis, Kostas
    Kapaki, Elisabeth
    NEUROLOGICAL SCIENCES, 2019, 40 (05) : 929 - 938